Partnerships / Investors

Sovereign-aligned biotech partnership.

We engage with strategic capital, ministries and research institutions across the U.S. ↔ GCC corridor to co-build a sovereign-scale regenerative platform.

GenREY is structured for sovereign-aligned engagement. That means our IP filings, manufacturing playbooks and clinical-trial protocols are all designed to be portable across regulatory jurisdictions — Saudi SFDA, U.S. FDA, UAE DHA and Qatar's MoPH — so partners across the corridor can plug in without forcing us to fork the platform.

Typical partnership models include: technology-transfer programmes for sovereign biotech build-out, clinical-trial-infrastructure co-deployment, manufacturing-localisation joint ventures, research-collaboration agreements with academic medical centres, and platform-level licensing for regenerative formulations and devices. Each is structured around Vision-2030 and equivalent national life-sciences strategies.

Strategic capital partners typically engage at the platform level — funding the R&D backbone, the omics + AI infrastructure, and the manufacturing / clinical-trial capacity that supports all seven programmes. We work with sovereign funds, family offices, life-sciences strategic and select institutional capital. Briefings are tailored to your investment mandate.

U.S. ↔ GCC

Corridor Footprint

$325M

Platform Vision

Vision 2030

Strategic Alignment

Active

LOIs in Pipeline

Partnerships & Investors

A sovereign biotech corridor between America and the Gulf.

Built for ministries, sovereign funds, sovereign-investment vehicles and institutional partners across Saudi Arabia, Qatar and the UAE — translating U.S. innovation into regional life-sciences leadership.

Vision-2030 alignment

U.S. ↔ GCC pillar

Technology transfer

U.S. ↔ GCC pillar

Manufacturing localization

U.S. ↔ GCC pillar

Clinical-trial infrastructure

U.S. ↔ GCC pillar

U.S. Hub

U.S. Innovation Hub